Charité - Universitätsmedizin Berlin nominated for Falling Walls Global Call - Life Sciences
MARC DEWEY from CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN ist nominated with his project "Breaking the Wall to Noninvasive Imaging of Coronary Artery Disease."
MARC DEWEY from CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN ist nominated with his project "Breaking the Wall to Noninvasive Imaging of Coronary Artery Disease."
GQ Bio Therapeutics GmbH today announced that it has closed a collaboration deal with Pacira BioSciences, Inc. for the development of a manufacturing process for its High-Capacity Adenoviral vector (HCAd) gene therapy product candidate, PCRX-201,…
Combined Company Expected to Expand Access for Patients to Innovative Rehabilitation Technologies for Use in Clinics and the Home
Charles Remsberg Appointed Chief Sales Officer at ReWalk Robotics
Expansion of capabilities provides customised bioconjugation solutions for Pharma and IVD industries
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 10% to € 118.0 million in the first half of 2023.
With a grant of 600,000 euros, the Einstein Foundation Berlin is funding the preliminary module for an Einstein Center for Early Disease Interception. Ten Berlin institutions – including the Max Delbrück Center – are looking to develop, integrate and…
We are proud to announce that MyoPax has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for its innovative regenerative cell therapy for Exstrophy-Epispadias-Complex.
Charité – Universitätsmedizin Berlin and the Samsung Comprehensive Cancer Center in Seoul have signed a memorandum of understanding. As part of this partnership, the Charité Comprehensive Cancer Center (CCCC) and the Samsung Comprehensive Cancer…
The stem cell therapy developed by MyoPax, a spin-off from the Max Delbrück Center and Charité, could soon be helping children with previously incurable muscle diseases thanks to an accelerated approval process. The necessary clinical trial will…
DEEP – Institute for Deep Tech Innovation at ESMT Berlin has signed a three-year partnership agreement with Bayer to jointly strengthen the translation of cutting-edge technologies in life sciences as well as biotech and healthtech startups.